Journal of Antimicrobial Chemotherapy, Vol 39, 75-80, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
JW Mouton, HP Endtz, JG den Hollander, N van den Braak and HA Verbrugh
The activity of quinupristin/dalfopristin was compared with that of other
widely used antibiotics against 355 strains isolated from patients with
endocarditis. MICs were determined by a standard agar dilution method.
Quinupristin/dalfopristin was inhibitory at 1 mg/L for all
coagulase-negative staphylococci (n = 36) and for the majority of
Staphylococcus aureus strains (n = 87). The activity of
quinupristin/dalfopristin against 186 viridans streptococci was somewhat
dependent on the species, with MIC50s ranging from 0.5 to 2 mg/L, being
least active against Streptococcus bovis and most active against
Streptococcus gordonii and Streptococcus mitis. For the staphylococci,
quinupristin/dalfopristin was as active against erythromycin-susceptible as
erythromycin-resistant strains. Viridans streptococci showed a slight but
significant correlation between sensitivity to erythromycin and
quinupristin/dalfopristin. It is concluded that quinupristin/dalfopristin
has the potential to treat serious infections such as endocarditis caused
by Gram-positive cocci.
ORIGINAL ARTICLES
In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis
Department of Clinical Microbiology, Erasmus University Hospital Rotterdam, The Netherlands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. B. Landersdorfer, C. M. J. Kirkpatrick, M. Kinzig-Schippers, J. B. Bulitta, U. Holzgrabe, G. L. Drusano, and F. Sorgel Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3290 - 3297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Olsen, M. Gentry-Nielsen, M. Yue, M. U. Snitily, and L. C. Preheim Effect of Ethanol on Fluoroquinolone Efficacy in a Rat Model of Pneumococcal Pneumonia Antimicrob. Agents Chemother., January 1, 2006; 50(1): 210 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-J. Teng, P.-R. Hsueh, S.-W. Ho, and K.-T. Luh High Prevalence of Inducible Erythromycin Resistance among Streptococcus bovis Isolates in Taiwan Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3362 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gander and R. Finch The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria J. Antimicrob. Chemother., July 1, 2000; 46(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Aeschlimann, E. Hershberger, and M. J. Rybak Activities of Trovafloxacin and Ampicillin-Sulbactam Alone or in Combination versus Three Strains of Vancomycin- Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1153 - 1158. [Abstract] [Full Text]
|
|
|
|
|
|
J. S. Bradley, G. L. Kearns, M. D. Reed, E. V. Capparelli, J. Vincent, and The Pediatric Pharmacology Research Unit Network Pharmacokinetics of a Fluoronaphthyridone, Trovafloxacin (CP 99,219), in Infants and Children following Administration of a Single Intravenous Dose of Alatrofloxacin Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1195 - 1199. [Abstract] [Full Text]
|
|
|
|
|
|
M. Backo, E. Gaenger, A. Burkart, Y. L. Chai, and A. S. Bayer Treatment of Experimental Staphylococcal Endocarditis Due to a Strain with Reduced Susceptibility In Vitro to Vancomycin: Efficacy of Ampicillin-Sulbactam Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2565 - 2568. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. W. Amsden, D. M. Graci, L. J. Cabelus, and L. G. Hejmanowski A Randomized, Crossover Design Study of the Pharmacology of Extended-Spectrum Fluoroquinolones for Pneumococcal Infections Chest, July 1, 1999; 116(1): 115 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ng, I. Lutsar, L. Wubbel, F. Ghaffar, H. Jafri, G. H. McCracken, and I. R. Friedland Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia J. Antimicrob. Chemother., June 1, 1999; 43(6): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hershberger, J. R. Aeschlimann, T. Moldovan, and M. J. Rybak Evaluation of Bactericidal Activities of LY333328, Vancomycin, Teicoplanin, Ampicillin-Sulbactam, Trovafloxacin, and RP59500 Alone or in Combination with Rifampin or Gentamicin against Different Strains of Vancomycin-Intermediate Staphylococcus aureus by Time-Kill Curve Methods Antimicrob. Agents Chemother., March 1, 1999; 43(3): 717 - 721. [Abstract] [Full Text]
|
|